18 Feb 2010 09:04
18 February 2010
Akers Biosciences, Inc.
("ABI" or the "Company")
Director/PDMR Shareholding
ABI, a leading designer and manufacturer of rapid diagnostic screening and testing products, announces the following acquisitions of shares in the Company by a director, a former director and a person disseminating managerial responsibility:
Edward Mulhare, Non-executive Director, has converted $30,000 of director's fees into 131,549 common shares at par value increasing his shareholding in the Company to 1,548,364 common shares, representing approximately 1.36 per cent. of the enlarged issued share capital.
Leroy J. Meyers, VP Operations has exercised warrants over 131,549 common shares at par value and purchased 100,000 common shares at par value increasing his shareholding in the Company to 405,732 common shares, representing approximately 0.35 per cent. of the enlarged issued share capital.
The estate of former director Daniel Seckinger has converted $11,250 of director's fees into 49,342 common shares at par value increasing his shareholding in the Company to 648,769 common shares, representing approximately 0.57 per cent. of the enlarged issued share capital.
The new common shares rank pari passu with the Company's existing issued common shares. Application has been made for the 412,440 common shares to be admitted to trading on AIM, and dealings are expected to commence on 23 February 2010.
Following Admission, the Company's enlarged issued share capital will comprise 114,405,322 common shares with voting rights. The Company does not hold any shares in treasury. This figure of 114,405,322 common shares may be used by shareholders in the Company as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change in their interest in, the share capital of the Company under the FSA's Disclosure and Transparency Rules.
Enquiries:
Thomas A. Nicolette
President and CEO
Tel. +1 856 848 8698
Alasdair Younie
Arbuthnot Securities Limited
Tel. +44 (0)20 7012 2000
Ben Simons
M:Communications
Tel. +44 (0)20 7153 1540
END